Clozapine treatment of psychosis in Parkinson's disease : a report of five consecutive cases

摘要: BACKGROUND Clozapine has gained acceptance as an antipsychotic in treatment-resistant schizophrenia. Its low propensity to induce extrapyramidal side effects makes clozapine attractive treatment for patients with Parkinson's disease and dopaminomimetic psychosis. Recent evidence demonstrates that are exquisitely sensitive both the potential of clozapine. The uncontrolled studies suggest low-dose may be efficacious this population. dose range, effect profiles, length varied these reports. METHOD We report our experience five psychosis who were treated open trial. RESULTS Three successfully (25-100 mg/day, mean = 66.7 mg) without worsening their parkinsonism. Adverse unrelated motor disability required discontinuation other two patients. At 1- 2-year follow-up, each patient had increased dosages (75-150 125 continued management higher range was well tolerated. CONCLUSION These results effectively treat disease.